Incyte Corporation INCY
123.36
(1.46)
(1.17%)
as of 29 Sep
- Market cap
- $26.1B
- P/E
- 15.4×
Follow INCY
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Incyte Corporation (INCY) Gross margin
Incyte Corporation's gross margin over the twelve months to 30 June 2026 was 92.6%, down 0.1 percentage points from fiscal 2025 (92.8%). Over the past ten years it has ranged from 92.6% (fiscal 2024) to 96.4% (fiscal 2015); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.7%.
Gross margin, annual
Annual
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 92.8% | 0.12 |
| FY2024 | 92.6% | (0.46) |
| FY2023 | 93.1% | (0.80) |
| FY2022 | 93.9% | (1.04) |
| FY2021 | 94.9% | (0.14) |
| FY2020 | 95.1% | 0.37 |
| FY2019 | 94.7% | (0.29) |
| FY2018 | 95.0% | 0.17 |
| FY2017 | 94.8% | 0.09 |
| FY2016 | 94.7% | (1.68) |
Quarterly
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 93.7% | 1.94 |
| Mar 2026 | 91.8% | (0.17) |
| Dec 2025 | 92.0% | (0.79) |
| Sep 2025 | 92.8% | (0.77) |
| 42 more quarters | Free account |
Against its own ten years
Low 92.6%
High 96.4%
Ten-year median
94.7%
Current reading's percentile
18
Gross margin against peers
| Company | Gross margin |
|---|---|
| RPRX Royalty Pharma PLC compare | 100.0% |
| GMAB Genmab A/S Sponsored ADR compare | 93.0% |
| INCY Incyte Corporation | 92.6% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 88.9% |
| JAZZ Jazz Pharmaceuticals PLC compare | 88.4% |
| INSM Insmed, Inc. compare | 83.5% |
| ROIV Roivant Sciences Ltd. compare | 81.2% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 79.7% |
| BNTX BioNTech SE Sponsored ADR compare | 75.2% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.7% |
| Market median | 46.3% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement